1. Kim MK, Ko SH, Kim BY, Kang ES, Noh J, Kim SK, Park SO, Hur KY, Chon S, Moon MK, Kim NH, Kim SY, Rhee SY, Lee KW, Kim JH, Rhee EJ, Chun S, Yu SH, Kim DJ, Kwon HS, Park KS. Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019; 43:398–406.
2. Ko SH, Han K, Lee YH, Noh J, Park CY, Kim DJ, Jung CH, Lee KU, Ko KS. Task Force Team for the Diabetes Fact Sheet of the Korean Diabetes Association. Past and current status of adult type 2 diabetes mellitus management in Korea: a National Health Insurance Service Database Analysis. Diabetes Metab J. 2018; 42:93–100.
3. Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care. 2014; 37:2884–2894.
4. Lee CS, Kim YG, Cho HJ, Park J, Jeong H, Lee SE, Lee SP, Kang HJ, Kim HS. Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation. Sci Rep. 2016; 6:29393.
5. Chung YR, Ha KH, Kim HC, Park SJ, Lee K, Kim DJ. Dipeptidyl peptidase-4 inhibitors versus other antidiabetic drugs added to metformin monotherapy in diabetic retinopathy progression: a real world-based cohort study. Diabetes Metab J. 2019; 43:640–648.
6. Kim NH, Choi J, Kim NH, Choi KM, Baik SH, Lee J, Kim SG. Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: a population-based study. Diabetes Metab. 2018; 44:361–367.
7. Yun JS, Lim TS, Cha SA, Ahn YB, Song KH, Choi JA, Kwon J, Jee D, Cho YK, Park YM, Ko SH. Clinical course and risk factors of diabetic retinopathy in patients with type 2 diabetes mellitus in Korea. Diabetes Metab J. 2016; 40:482–493.
8. Park S, Rhee SY, Jeong SJ, Kim K, Chon S, Yu SY, Woo JT. Features of long-standing Korean type 2 diabetes mellitus patients with diabetic retinopathy: a study based on standardized clinical data. Diabetes Metab J. 2017; 41:393–404.
9. Secrest MH, Udell JA, Filion KB. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. Trends Cardiovasc Med. 2017; 27:194–202.